Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes
- 312 Downloads
The purpose of this study was to assess the effects of PPAR-γ agonists (pioglitazone and rosiglitazone) on mediators of endothelial dysfunction and markers of angiogenesis in patients with type-2 diabetes. Pioglitazone group showed favorable reductions in serum total cholesterol, triglycerides, LDL cholesterol, VLDL cholesterol and increase in HDL cholesterol as compared to rosiglitazone group, after 16 weeks of treatment and also with control group. There was significant reduction of CRP level in pioglitazone and rosiglitazone group. The level of serum TNF-α decreased significantly in pioglitazone and mildly decreased in rosiglitazone group. The level of VEGF, IL-8 and Angiogenin were increased in pioglitazone than rosiglitazone group. There were no significant changes observed in the serum angiogenin and IL-8 levels in the control group. Pioglitazone and rosiglitazone therapy in type-2 diabetes subjects have additional benefits of reducing mediators of endothelial dysfunction. Increase in angiogenesis markers in patients receiving pioglitazone could have variable effects in diabetic nephropathy and retinopathy as there may be increased vascular neogenesis. Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines.
KeywordsPPAR-γ agonists Diabetic nephropathy Diabetic retinopathy Vascular neogenesis
Authors Mr. Manish Mishra and Mr. Hemant Kumar are thankful to UGC, India, for financial support. Authors are also thankful to Dr. R. K. Singh, Department of Biochemistry and Radheyshyam Maurya, Department of Medicine for their support and help.
- 1.Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriocler Thromb Vasc Biol 19:972–978Google Scholar
- 3.Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:2058–2067PubMedCrossRefGoogle Scholar
- 13.Favard C, Ortega N, Bayard F, Plouet J (1996) Vascular endothelial growth factor and retinal neovascularisation : a new therapeutic approach for diabetic retinopathy. Diabetes Metab 22:368–373Google Scholar
- 14.Sharma NK, Gardiner TA, Archer DB (1985) A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Opthalmol 100:51–60Google Scholar
- 18.Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators (2005) A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type-2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554PubMedCrossRefGoogle Scholar
- 19.Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24:378–396PubMedCrossRefGoogle Scholar
- 22.Cabrero A, Cubero M, Llaverías G, Jové M, Planavila A, Alegret M, Sánchez R, Laguna JC, Carrera MV (2003) Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52:652–657PubMedCrossRefGoogle Scholar
- 26.Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 39:82–86Google Scholar
- 28.Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A (2000) Vascular endothelial growth factor in children, adolescents and young adults with type-1 diabetes mellitus: relation to glycemic control and microvascular complications. Diabet Med 17:650–656PubMedCrossRefGoogle Scholar